The use of preclinical pharmacokinetic and pharmacodynamic data to predict clinical doses: current and future perspectives

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Unknown venue

• Publication date

  2001-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0531-5131(01)00282-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of fluconazole in people with HIV infection: a population analysis.

  2003cited by this paper
• Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.

  1999cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport.

  1998cited by this paper
• Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics.

  1998cited by this paper
• Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine

  1998cited by this paper
• Managing the drug discovery/development interface

  1997cited by this paper
• Pharmacokinetics and bioavailability of montelukast sodium (MK‐0476) in healthy young and elderly volunteers

  1997cited by this paper
• Role of Pharmacokinetics and Metabolism in Drug Discovery and Development

  1997cited by this paper
• The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

  1997cited by this paper
• Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs.

  1997cited by this paper
• Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

  1996cited by this paper
• Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance.

  1996cited by this paper
• Animal Pharmacokinetics and Interspecies Scaling from Animals to Man of Lamifiban, a New Platelet Aggregation Inhibitor

  1996cited by this paper
• Interspecies scaling: predicting clearance of drugs in humans. Three different approaches.

  1996cited by this paper
• Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection

  1995cited by this paper
• Success rates for new drugs entering clinical testing in the United States

  1995cited by this paper
• Species similarities and differences in pharmacokinetics.

  1995cited by this paper
• Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist.

  1995cited by this paper
• First‐Time‐in‐Human Dose Selection: Allometric Thoughts and Perspectives

  1995cited by this paper
• Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

  1994cited by this paper
• Fluconazole: Interspecies Scaling and Allometric Relationships of Pharmacokinetic Properties

  1994cited by this paper
• Prediction of therapeutic doses of beta-adrenergic receptor blocking agents based on quantitative structure-pharmacokinetic/pharmacodynamic relationship.

  1993cited by this paper
• Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.

  1993cited by this paper
• The allometric approach for interspecies scaling of pharmacokinetic parameters.

  1992cited by this paper
• Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man.

  1992cited by this paper
• A population study of the pharmacokinetics of felodipine.

  1991cited by this paper
• Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).

  1988cited by this paper
• Population study of triazolam pharmacokinetics.

  1986cited by this paper
• Man versus beast: pharmacokinetic scaling in mammals.

  1986cited by this paper
• Physiologically based pharmacokinetic modeling: principles and applications.

  1983cited by this paper
• A physiological approach to hepatic drug clearance

  1975cited by this paper

• Prediction of pharmacokinetics of an anaplastic lymphoma kinase inhibitor in rat and monkey: application of physiologically based pharmacokinetic model as an alternative tool to minimise animal studies

  2023cites this paper
• Maximizing tumour exposure to anti‐neuropilin‐1 antibody requires saturation of non‐tumour tissue antigenic sinks in mice

  2012cites this paper